Syngene International Ltd (SYNGENE) is currently trading at 448.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Syngene International is an integrated research, development, and manufacturing services company supporting pharmaceutical, biotechnology, nutrition, animal-health, consumer-goods, and specialty-chemical customers through CRO and CDMO offerings. Its operations span discovery, translational and clinical research, dedicated centers, and contract development and manufacturing across India and the United States. The company is attempting a meaningful business-model reset: Discovery Services is moving away from commoditized FTE work toward integrated, AI-enabled, fee-for-service offerings, while CDMO is being established as the principal long-term growth engine. Management views this transition as necessary to protect margins and differentiate Syngene from lower-cost CRO competitors. Quarterly recovery was visible but remains early. Revenue increased 13% sequentially to INR833 crore, operating EBITDA margin improved six percentage points to 18%, and profit after tax returned to INR32 crore from a previous-quarter loss. However, revenue remained 9% below the prior-year quarter, partly because Zoetis revenue was absent. Syngene’s India-U.S. biologics model is becoming a central strategic differentiator. Bayview’s first manufacturing agreement, India-based process development, and U.S.-based future drug-substance production offer customers supply-chain flexibility amid geopolitical and regulatory concerns, while the company claims meaningful biologics scale and integrated capabilities unavailable from many Indian competitors. The balance sheet provides transformation capacity, with INR1,392 crore of net cash at quarter-end and approximately INR200 crore invested during the first half. Nevertheless, management acknowledges that Bayview ramp-up, Discovery Services rebuilding, capacity utilization, and sustainable profitability will require several quarters rather than being resolved by one improved quarter.

Over the past 52 weeks, Syngene International Ltd has traded between a low of ₹344.85 and a high of ₹678.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Syngene International Ltd has a market capitalization of approximately 17,874.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Syngene International Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 96.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 17,874.47 Cr, Syngene International Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Syngene International Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Syngene International Ltd is 96.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

It covers the quarter and nine months ended December 31, 2025.

Syngene International is scheduled to announce its Q2 FY27 earnings on October 27, 2026.

Consolidated revenue from operations in Q1 FY27 fell 16% year-on-year to Rs 736 crore. Standalone revenue from operations was reported at Rs 663 crore.

The 33rd AGM is scheduled for Wednesday, July 29, 2026 at 3:30 pm IST and will be held via VC/OAVM.